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Abstract—Given the lack of evidence in support of pacing 
self-management for patients with chronic fatigue syndrome 
(CFS), we examined whether physical behavior and health sta-
tus of patients with CFS would improve in response to a pacing 
self-management program. We performed an observational 
study of pacing self-management in seven CFS patients using a 
single-case study design. Stages A1 and A2 (7-day assessment 
periods) of the A1-B-A2 design corresponded to the baseline 
and posttreatment measurements of physical behavior (real-
time activity monitoring) and health status (self-reported meas-
ures), respectively. Stage B (3 weeks of treatment) consisted of 
three individual treatment sessions of pacing self-management. 
When comparing pre- versus posttreatment data, we found that 
the patients’ ability to perform daily activities and the severity 
of their symptom complexes were improved (p = 0.043). Con-
centration difficulties, mood swings, muscle weakness, and 
intolerance to bright light improved as well. A statistically sig-
nificant decrease in the mean time spent doing light activity 
(<3 metabolic equivalents) was observed, but a change in the 
way physical activity was spread throughout the day was not. 
We found that 3 weeks of pacing self-management was accom-
panied by a modest improvement in symptom severity and daily 
functioning. The outcome of the present study calls for a ran-
domized controlled clinical trial to examine the effectiveness 
of pacing self-management for people with CFS.
Key words: activity, activity peak, behavior, CFS, chronic 
fatigue, pacing, rehabilitation, self-management, syndrome, 
therapy.
INTRODUCTION
People with chronic fatigue syndrome (CFS) often 
report a fluctuating pattern to their symptoms, including 
their physical and cognitive capabilities. A clinical study 
of CFS patients showed high variability in mental and 
physical fatigue over a 4-week period [1]. Too vigorous 
exercise [2–4] or even a 30 percent increase in activity 
[5] can frequently trigger a relapse, which may conse-
quently explain at least part of the fluctuating symptom 
pattern commonly seen in CFS. In-line with these results 
are the findings that (1) the lifestyle of CFS patients is 
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rest periods [6], (2) a premorbid overactive lifestyle may 
play a predisposing and/or initiating role in CFS [7], and 
(3) continuing to be active despite increasing fatigue is 
likely to be a crucial step in the development of CFS [8]. 
It has been shown that specific activities, which were 
expected to result in high fatigue levels, were less fre-
quently performed by CFS patients and, furthermore, that 
high fatigue expectations were related to low activity lev-
els [9]. On the other hand, during short periods, patients 
with CFS are generally able to perform light to moderate 
activity or exercise (40% of peak oxygen capacity) with-
out exacerbating their symptoms or affecting their cogni-
tive performance [10–11].
From these findings, including activity management 
in the comprehensive treatment of people with CFS 
seems plausible. Activity management is generally 
included in cognitive behavioral programs for CFS, and 
evidence exists that supports the effectiveness of cogni-
tive behavioral therapy for patients with CFS [12]. Up to 
date, no data have been published on the extent to which 
activity management contributes to the effectiveness of 
cognitive behavioral therapy. Cognitive behavioral 
therapy could possibly be equally as effective without the 
inclusion of activity management. However, cognitive 
behavioral therapy might rely (in part) on activity man-
agement for its effectiveness. In addition, the availability 
of cognitive behavioral therapy for CFS patients in many 
countries is limited because of a lack of therapists. Cog-
nitive behavioral therapists often work in specialized 
fatigue centers, which leads to capacity problems and 
practical barriers to those patients who live long dis-
tances from these centers. Other cognitive behavior ther-
apists work in private practices, which generates 
financial obstacles for the patients. For all these reasons, 
studies examining the potential benefits of less time-
consuming treatments are warranted.
Graded exercise therapy has been reported to be 
effective for CFS [13] and is included in many cognitive 
behavioral therapy programs for CFS. Although no evi-
dence currently exists that graded exercise therapy, on 
average, causes harm to CFS patients [13], preventing 
exercise-induced exacerbations in symptoms when 
applying exercise therapy to patients with CFS remains 
important, especially in terms of treatment compliance 
[14]. Initial success of exercise therapy in CFS is most 
likely due to the patients realizing that exercise can be 
safely undertaken without the consequence of relapse. 
This realization assists CFS patients in abandoning any 
avoidance behaviors to which they may have previously 
adhered [15]. Therefore, a self-management program that 
teaches people with CFS to explore all kinds of physical 
activity appropriate for their individual physical capabili-
ties appears necessary. These types of self-management 
techniques used together with, or prior to, a graded exer-
cise program appear warranted for people with CFS [14].
Self-management for people with CFS involves 
encouraging the patients to pace their activities and 
respect their physical and mental limitations [16–17]. 
This strategy has been termed “pacing” and involves 
encouraging the patient to achieve an appropriate balance 
between activity and rest in order to avoid exacerbating 
his or her symptoms. It requires the patient to set realistic 
activity goals on a daily basis [16,18] and to regularly 
monitor and manipulate activity in terms of intensity, 
duration, and rest periods in order to avoid possible over-
exertion, which can worsen symptoms [16,18]. Pacing 
takes into account the considerable fluctuations in symp-
tom severity [16] and delayed recovery from exercise 
that typically occur in patients with CFS [19]. The pacing 
approach is in-line with recent observations regarding the 
interactions between malfunctioning of the immune sys-
tem, physical activity, and symptoms in CFS patients 
[14]. It advocates a symptom-contingent rather than a 
time-contingent approach. In addition, some patients 
with CFS are reluctant to undertake psychological treat-
ments, such as cognitive behavioral therapy, for what 
they believe to be a physical condition. Pacing self-
management techniques encourage a behavioral change 
and at the same time acknowledge the physical aspects of 
the illness.
Given the lack of evidence in support of pacing self-
management as a sole treatment for those with CFS,
we undertook an observational study of pacing self-
management in seven CFS patients using a single case 
study design. We examined whether pretreatment physical
behavior and health status of patients with CFS differed 
from posttreatment physical behavior and health status. 
The outcome of the present single case study will allow 
us to judge the feasibility of setting up a randomized 
controlled clinical trial to examine the effectiveness of 
pacing self-management for people with CFS.
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Patients
Fifteen adult women who fulfilled Centers for Dis-
ease Control and Prevention diagnostic criteria for CFS 
[20] were contacted, seven of whom participated in the 
study. All participants were recruited from a specialized 
university-based chronic fatigue center, were within the 
age range of 18 to 65, spoke Dutch as their native lan-
guage, and provided written informed consent for study 
participation. Patients who previously received activity 
management or behavioral therapy were deemed inap-
propriate for study participation. The study protocol was 
approved by the local ethical committee.
Design
A single case study with an A1-B-A2 design was 
used. All study participants had to attend the university 
hospital on five different occasions at 1-week intervals 
(Figure 1 displays the study flow diagram). During their 
initial visit, participants were asked to read the informa-
tion leaflet, given the opportunity to ask for additional 
information, and asked to sign the informed consent 
form. To account for bias related to cointerventions, we 
explained to the study participants that they were allowed 
to continue their ongoing medical treatment but under no 
circumstances were they to initiate a new medical or con-
servative treatment. They were then asked to fill in a 
number of self-report questionnaires: the Chronic Fatigue 
Syndrome-Activities and Participation Questionnaire 
(CFS-APQ), CFS Symptom List, Medical Outcomes 
Study 36-Item Short Form Health Survey (SF-36), and 
Checklist Individual Strength (CIS). The order of ques-
tionnaire administration was randomized to account for 
test order bias. To prevent administration bias, we had 
patients fill out the questionnaires personally without 
input or feedback. Next, we assessed the patient’s ability 
to perform daily activities using the Canadian Occupa-
tional Performance Measure (COPM).
After filling out the questionnaires, the patients 
entered stage A1 of the A1-B-A2 design. Stage A1 corre-
sponded to the baseline measurement of physical behav-
ior prior to treatment (stage B) commencement. During 
stage A1, participants continuously wore an acceler-
ometer for real-time activity monitoring. Height, weight, 
and sex were entered before attaching the accelerometer 
on the nondominant wrist and securing it with an adhesive
band. We explained the use of the device and instructed 
the patient to wear it 24 hours a day until the second 
appointment 1 week later. Besides wearing the acceler-
ometer, patients were instructed to keep an activity diary; 
to rate their fatigue severity, pain severity, and concentra-
tion difficulties twice a day on a visual analog scale 
(VAS); and to complete the CFS Symptom List every 
evening.
At their second appointment (day 8 of the study and 
termination of stage A1), the participants received their 
first individual treatment session (initiation of stage B: 
Figure 1). Stage B lasted for 3 consecutive weeks and 
consisted of one individual treatment session a week for a 
total of three treatment sessions. The physiotherapists who 
led the treatment sessions were not involved in any of the
measurements (blind assessments and blinded therapists).
The final treatment session (week 4) corresponded to 
the termination of stage B and the initiation of stage A2. 
Thus, after their final treatment session, patients were 
instructed to once again wear an accelerometer 24 hours 
a day until the final appointment 1 week later. As was the 
case during stage A1, they were instructed to keep an 
activity diary; to rate their fatigue severity, pain severity, 
and concentration difficulties twice a day on a VAS; and 
to complete the CFS Symptom List every evening. Dur-
ing their final appointment (week 5), participants were 
asked to complete the same set of questionnaires as dur-
ing their initial visit. Again, the order of the question-
naires was randomized and patients had to fill out the 
questionnaires personally without input or feedback from 
the investigators. Finally, the same investigator assessed 
the patient’s ability to perform daily activities using the 
COPM.
Questionnaires
The SF-36 assesses functional status and well-being, 
or quality of life [21]. The SF-36 has been documented to 
have reliability and validity in a wide variety of patient 
populations [21–23], and it is the most frequently used 
measure in CFS research [24].
The CFS Symptom List is a self-report measure for 
assessing symptom severity in CFS patients. In order to 
assess the severity of the symptoms included in the CFS 
Symptom List, we used VASs (100 mm). Psychometric 
work supporting the use of the CFS Symptom List has 
been published [25–26].
The CFS-APQ is a self-administered questionnaire 
aimed at monitoring activity limitations and participation 
restrictions in patients with CFS. A total score of 1 indicates 
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16 represents the maximum score. Data documenting the 
clinometric properties of the Dutch CFS-APQ are avail-
able [27–28].
The CIS aims at assessing subjective fatigue experi-
ence, concentration difficulties, motivation, and physical 
activity [29]. Higher scores on the CIS correspond to 
severe fatigue, many concentration difficulties, problems 
with motivation, and a low level of physical activity. Its 
psychometric properties are well established [29–31].
The COPM uses a semistructured interview for the 
assessment of the patient’s ability to perform activities of 
Figure 1.
Study flow diagram. CDC = Centers for Disease Control and Prevention, CFS = chronic fatigue syndrome, CFS-APQ = Chronic Fatigue 
Syndrome-Activities and Participation Questionnaire, CIS = Checklist Individual Strength, COPM = Canadian Occupational Performance 
Measure, SF-36 = Medical Outcomes Study 36-Item Short Form Health Survey, VAS = visual analog scale.
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and leisure time [32]. During the semistructured inter-
view, the assessment is focused on the patient’s personal 
problems in commencing daily activities that are impor-
tant to the patient’s living environment. The COPM gen-
erates two subscale scores: the performance score 
indicates the ability of the patient to perform daily activi-
ties and the satisfaction score corresponds to the patient’s 
satisfaction with daily activities. The clinometric proper-
ties of the COPM are well established [32–35].
Assessment of Physical Behavior
The Actical (Mini Mitter; Bend, Oregon) acceler-
ometer was used for real-time monitoring of physical 
behavior. The Actical accelerometer has an omnidirec-
tional sensor and is capable of measuring movement in 
one plane. The sensor functions via a cantilevered rectan-
gular piezoelectric bimorph plate and seismic mass and is 
capable of detecting movements in the 0.5 to 3 Hz range. 
Voltage generated by the sensor is amplified and filtered 
via analog circuitry. The amplified and filtered voltage is 
passed into an analog to digital converter, and the process 
is repeated 32 times per second (32 Hz). The resulting 
per second value is divided by four and then added to an 
accumulated activity value (activity counts) for the 
epoch. The Actical is the smallest accelerometer avail-
able (28 × 27 × 10 mm, 17 g) and is water-resistant. 
Accelerometers are the gold standard for measuring 
physical behavior during daily activities. The Actical 
accelerometer has been used in scientific research and 
has been shown to be valid for the real-time assessment 
of physical behavior [36]. For the present study, the moni-
tors were initialized to save data in 1-minute intervals 
(epochs).
Apart from wearing an accelerometer, patients were 
instructed to report their physical behavior in an activity 
diary. For each day, the activity diary consisted of a large 
table with four columns for filling out (1) the type of 
activity, (2) the initiation and termination time for each 
activity, (3) any health status changes (e.g., increase of 
fatigue in response to ironing), and (4) the total activity 
duration and corresponding metabolic equivalent (MET) 
values (to be completed by the investigators). Partici-
pants were instructed to specify their activities in detail 
immediately in order to avoid mistakes in recall. The 
activity diary also contained two sets of VASs (for 
fatigue severity, pain severity, and concentration difficul-
ties) to be completed in the morning and at noon (imme-
diately after lunch) and a CFS Symptom List (to be 
completed in the evening). Participants started with the 
activity diary the morning after the first appointment and 
were instructed to keep on doing so until the second 
appointment 1 week later. Apart from the VASs, no infor-
mation or data generated with the activity dairy were 
used for further analysis. The activity diary was used by 
the therapists to coach the patient in the pacing self-
management program. More specifically, the activity diary
was used to identify activity peaks, to confront the patient,
and to discuss solutions for the activities of interest.
Treatment: Pacing Self-Management
The pacing self-management program focused on 
teaching the patients to estimate their current physical 
capabilities prior to commencing an activity. In order to 
appropriately pace activities (daily activities and exercise 
bouts), CFS patients had to learn to estimate their current 
physical capabilities prior to commencing an activity, 
keeping in mind the regular fluctuating nature of their 
symptoms. Daily activities were defined as those duties 
typically performed around the home and at work, such 
as ironing, shopping, housework, gardening, etc. The 
activity duration used within the program was less than 
the reported duration to account for typical overestima-
tions made by patients. Each activity block was inter-
spersed with breaks, with the length of the break equating 
to the duration of the activity. This procedure was fol-
lowed in order to account for the delayed recovery from 
exercise commonly demonstrated in CFS patients [19]. 
“Breaks” were defined as relative rest periods, with the 
patient just relaxing or performing a different type of 
light activity (for example, in a break between two iron-
ing sessions, the patient was allowed to perform a light 
mental activity such as reading).
Employing the pacing principles during a CFS 
patient’s daily life implicates a behavioral change. Thus, 
care was taken to explain the rationale and potential ben-
efits of the program prior to commencement, while the 
patient’s expectations for care were taken into account 
and subsequently used to encourage adherence to the pro-
gram. We provided participants with a booklet that 
explained the treatment rationale and practical approach. 
When the patient with CFS is able to manage his or her 
daily activity (i.e., symptom fluctuation is reduced to a 
manageable level) (stabilization phase), the therapist can 
then start to progress activity and exercise levels (grading 
phase). However, in the present study, only the stabilization
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ence between pacing self-management and cognitive 
behavioral therapy is that the latter postulates that activity 
levels can be substantially increased by a time-contingent 
approach and that a recovery from CFS is possible. The 
treatment as applied in the present study is described 
elsewhere [14].
Data Analysis
Data were analyzed with SPSS, version 16.0 (SPSS 
Inc; Chicago, Illinois). Given the small number of study 
participants, nonparametric and appropriate descriptive 
statistics were used. The accelerometer data were subdi-
vided into four activity levels: sedentary activity (1 MET),
light activity (<3 METs), moderate activity (3–6 METs), 
and vigorous activity (>6 METs). The METs were com-
puted by the Actical software based on activity counts 
and demographic data of the participant. Besides the 
METs, the pure, untransformed data generated by the 
accelerometer were used: the mean ± standard deviation 
(SD) amount of daily physical activity, the amount of 
physical activity (i.e., activity counts) during the peak 
activity hour for each day (identified as the hour with the 
highest number of activity counts), and the peak ratio for 
each day (counted as the amount of physical activity during
the peak activity hour/mean amount of physical activity 
on that day). A high peak ratio indicated a stronger con-
centration of physical activity, while a low peak ratio 
suggested that the participant spread her physical activity 
throughout the day more equally.
The Wilcoxon signed rank test was used to compare 
pre- versus posttreatment data (variability): question-
naires completed during week 1 versus week 5, mean and 
SD symptom severity score for symptom fluctuations 
(both CFS Symptom List) during week 1 versus week 5, 
and mean activity value/SD of the accelerometer data 
(activity counts and METs) during week 1 versus 5. In 
order to account for missing data, we used the “last 
observation carried forward method” for intention-to-
treat analysis. The level of significance was set at 0.05. 
Clinically meaningful improvements of the SF-36 sub-
scale scores were counted and interpreted according to 
the method described by Vitorino et al. [37]. Effect sizes 
were calculated as Cohen’s d, with d defined as the dif-
ference between the two means divided by the pooled SD 
for those means. A d-value of 0.20 is described as small, 
0.50 as medium (moderate), and 0.80 as large.
RESULTS
At study entry, the seven female participants had a 
median age of 43 ± 13 years (range: 23–59), median 
weight of 69 ± 19 kg, median body length of 170 ± 6 cm, 
and a median illness duration of 96 ± 44 months (range: 
60–180). Two patients ended their cooperation during the 
program. One dropped out after the second appointment 
because of overlap between the treatment content of pre-
vious treatments (i.e., a multidisciplinary treatment pro-
gram including activity management), and a second 
patient dropped out after the third appointment because 
she could not see how another approach besides magne-
sium intake could benefit her.
The comparison of the pre- versus posttreatment 
questionnaire data (appointment 1 vs appointment 5) is 
presented in Table 1. The total score on the CFS Symp-
tom List, reflecting the severity of the entire symptom 
complex experienced by the patient, was improved (p = 
0.043; mean improvement = 7 ± 8 mm; effect size = 0.4). 
The CIS revealed a trend toward improved concentration 
difficulties (p = 0.066; effect size = 0.6), an observation 
strengthened by the decrease in VAS score for concentra-
tion difficulties (p = 0.043; mean improvement = 12 ±
10 mm). Furthermore, the severity of mood swings 
(mean improvement of 18 ± 19 mm), muscle weakness 
(mean improvement = 19 ± 18 mm), and intolerance to 
bright light (mean improvement = 22 ± 24 mm) of the 
CFS Symptom List decreased from appointment 1 to 
appointment 5 (p < 0.05).
At the posttreatment assessment, patients’ ability to 
perform daily activities improved (both subscale scores 
of the COPM; p = 0.043 with large effect sizes). Five of 
seven patients improved on both subscale scores, with a 
mean improvement (all seven patients) of 34 ± 31 percent 
for the performance subscale and 57 ± 60 percent for the 
satisfaction subscale. However, no change was found in 
activity limitations and participation restrictions (CFS-
APQ) or quality of life (SF-36) (p > 0.05). Clinically 
meaningful improvements in the SF-36 subscale scores 
were observed rarely.
The previous paragraphs present the comparison of 
the first with the final assessment day, and those data 
might have been biased by the fluctuating nature of CFS. 
If, by coincidence, all patients had a bad day during the 
first appointment and a good day during their final 
appointment (unrelated to the treatment response), then 
the comparison of the first with the final assessment day 
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completed the CFS Symptom List not only during the 
baseline and final assessment day but also every evening 
during the week prior to and immediately following treat-
ment. For each day, the mean symptom severity score of 
all participants together was counted and plotted (Figure 2),
revealing a positive change. Table 2 presents the change 
in mean symptom severity between week 1 (A1: pretreat-
ment) and week 5 (A2: posttreatment). The mean total 
score on the CFS Symptom List and the mean pain severity
improved from week 1 to week 5. When analyzing the SD
(as a measurement of fluctuation) of the scores obtained 
with the CFS Symptom List, we found no statistically 
significant change between week 1 and week 5 (data not 
shown).
Comparing the data generated by the accelerometer 
between week 1 and 5, we found a statistically significant 
decrease in the mean time spent doing light activity
(<3 METs) but no change in time spent doing sedentary 
(1 MET), moderate (3–6 METs), or vigorous activity 
(>6 METs) (Table 3). Furthermore, no changes in the 
mean amount of physical activity (i.e., activity counts) 
during the peak activity hour for each day, the total mean 
time spent active, or the way physical activity was spread 
throughout the day (i.e., the mean peak ratio) were found. 
To further analyze the fluctuating nature of the physical 
activity pattern, we compared the SD of the accelerometer 
data between week 1 and 5. No statistically significant 
changes were observed (data not shown).
Table 1.








p-Value* Effect Size:Cohen’s d
CFS-APQ 8.2 ± 1.7 7.7 ± 1.8 0.35 0.3
CIS Fatigue 47.3 ± 8.1 41.9 ± 9.9 0.14 0.6
CIS Concentration Difficulties 26.0 ± 5.5 22.3 ± 6.7 0.07 0.6
CIS Motivation 15.1 ± 6.6 15.1 ± 6.6 0.89 0
CIS Physical Activity 13.7 ± 4.8 10.6 ± 3.6 0.10 0.7
COPM Performance 3.7 ± 0.8 4.8 ± 1.3 0.043† 0.9
COPM Satisfaction 3.1 ± 0.9 4.7 ± 1.7 0.043† 1.2
CFS Symptom List Total Score 51.3 ± 17.5 44.1 ± 21.7 0.043† 0.4
VAS Fatigue 68.9 ± 19.7 62.4 ± 29.2 0.30 0.3
VAS Pain 50.1 ± 31.5 50.6 ± 32.9 0.67 0.0
VAS Concentration Difficulties 63.4 ± 28.3 51.9 ± 34.5 0.043† 0.4
VAS Muscle Weakness 61.4 ± 18.1 42.7 ± 31.2 0.043† 0.7
VAS Mood Swings 42.3 ± 15.4 25.0 ± 22.5 0.042† 0.9
VAS Intolerance to Bright Light 52.7 ± 27.4 30.3 ± 36.1 0.043† 0.7
SF-36 Bodily Pain 44.9 ± 18.8 49.0 ± 15.9 0.89 0.2
SF-36 Physical Functioning 42.1 ± 20.8 46.4 ± 16.8 0.22 0.2
SF-36 Role Limitations: Physical 
Functioning
39.3 ± 31.8 28.6 ± 30.4 0.08 0.3
SF-36 Role Limitations: Emotional 
Problems
57.1 ± 46.0 71.4 ± 40.5 0.32 0.3
SF-36 Social Functioning 48.2 ± 18.3 46.4 ± 21.3 0.32 0.1
SF-36 Mental Health 56.6 ± 12.5 60.0 ± 14.2 0.28 0.2
SF-36 Vitality 41.4 ± 13.8 41.4 ± 16.5 0.99 0
SF-36 General Health Perception 34.6 ± 12.6 29.5 ± 7.7 0.41 0.5
*p-values based on Wilcoxon signed rank test.
†p < 0.05.
CFS = chronic fatigue syndrome, CFS-APQ = CFS-Activities and Participation Questionnaire, CIS = Checklist Individual Strength, COPM = Canadian Occupa-
tional Performance Measure, SD = standard deviation, SF-36 = Medical Outcomes Study 36-Item Short Form Health Survey, VAS = visual analog scale.
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The present observational study showed that 3 weeks 
of pacing self-management in a small group of CFS 
patients was accompanied by a modest improvement in 
symptom severity, an improved ability to perform daily 
activities, and a change in physical behavior (i.e., a 
decrease in the mean time spent doing light physical 
activity). No group change in self-reported quality of life 
or activity limitations and participation restrictions was 
observed, but large effect sizes were observed for the 
patients’ ability to perform activities of daily living. 
Although the study design precludes causal interpreta-
tions of the results, these findings might point to short-
term benefits of pacing self-management for people diag-
nosed with the severe illness, CFS. The outcome of the 
present single-case study design calls for a randomized 
controlled clinical trial to examine the effectiveness of 
pacing self-management for people with CFS.
The main study findings were unlikely to be biased 
by the fluctuating nature of the health status of CFS 
patients. Indeed, the outcome of the comparison of the 
Figure 2.
Change in mean symptom severity between week 1 (A1: pretreatment) and week 5 (A2: posttreatment). (a) Change in mean total scores of the 
CFS Symptom List between week 1 and week 5. (b), (c), and (d) Change in mean pain severity, mean fatigue severity, and mean concentration 
difficulties, respectively. CFS = chronic fatigue syndrome.
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appointment (Table 1) was confirmed by the analysis 
(Table 2) and plotting (Figure 2) of the mean symptom 
severity score of all participants together throughout 
week 1 versus week 5. Thus, symptom severity improved 
from week 1 to week 5 for the CFS patients studied here 
and the effect sizes were moderate to small.
The change in physical behavior observed here is diffi-
cult to interpret; it might even be a negative finding. 
Apart from a decrease in the mean time spent doing light 
activity (<3 METs), no changes in physical behavior 
were observed. The pacing self-management program 
specifically targets behavioral change by attempting to 
spread the amount of physical activity throughout the day 
and stabilize the fluctuating nature of the physical activ-
ity pattern throughout the week. However, no change in 
the way physical activity was spread throughout the day 
(i.e., the mean peak ratio) or the fluctuating nature of the 
physical activity pattern was observed. This might be due 
to the inability of the program to alter these behavioral 
parameters, the small sample size, or the wrong choice of 
outcome parameters. The peak ratio for each day was 
counted as the amount of physical activity during the 
peak activity hour divided by the mean amount of physi-
cal activity on that day. Whether this represents a valid 
outcome parameter remains unclear.
A high dropout rate (2/7 or 28.6%) was observed. 
However, the results presented were based on intention-
to-treat analysis. We conclude that despite the high drop-
out rate, improvements in symptom severity, daily activity
performance, and physical behavior accompanied the pac-
ing self-management program. Given the lack of evidence
Table 2.
Change in mean symptom severity between week 1 (pretreatment) and week 5 (posttreatment).
Variable Week 1: Pretreatment (mean ± SD)
Week 5: Posttreatment
(mean ± SD) p-Value
*
CFS Symptom List Total Score 43.4 ± 19.1 33.9 ± 16.7 0.043† 
VAS Fatigue 63.7 ± 23.6 57.1 ± 23.9 0.14 
VAS Pain 44.9 ± 24.4 37.1 ± 22.2 0.03†
VAS Concentration Difficulties 49.9 ± 22.6 39.2 ± 22.5 0.08
*p-values based on Wilcoxon signed rank test.
†p < 0.05.
CFS = chronic fatigue syndrome, SD = standard deviation, VAS = visual analog scale.
Table 3.
Change in physical behavior assessed with accelerometer between week 1 (pretreatment) and week 5 (posttreatment).
Variable Week 1: Pretreatment (mean ± SD)
Week 5: Posttreatment 
(mean ± SD) p-Value
*
Total Mean Time Active (min) 235.2 ± 47.6 221.6 ± 27.9 0.89
Mean Time Sedentary Activity: 
1 MET (min)
746.6 ± 61.8 736.0 ± 48.1 0.35
Mean Time Light Activity: 
<3 METs (min)
567.5 ± 38.1 592.5 ± 38.8 0.043†
Mean Time Moderate Activity:
 3–6 METs (min)
125.8 ± 36.7 111.5 ± 21.5 0.69
Mean Time Vigorous Activity: 
>6 METs (min)
0.1 ± 0.2 0.1 ± 0.2 0.32
Mean Amount of Physical Activity 
(i.e., activity counts) During Peak Activity 
Hour for Each Day
829.9 ± 144.0 781.3 ± 179.5 0.67
Mean Peak Ratio (activity counts/activity 
counts)
3.6 ± 0.2 3.5 ± 0.5 0.67
*p-values are based on the Wilcoxon signed rank test.
†p < 0.05.
MET = metabolic equivalent, SD = standard deviation.
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or treatment component for those with CFS, comparison 
with other studies is impossible. The ongoing, large Pac-
ing, Graded Activity, and Cognitive Behavior Therapy: A 
Randomized Evaluation (PACE) trial [38] will provide 
more insight into the potential benefits of pacing self-
management for those with CFS.
A follow-up period was not included in the present 
study, which means that we have no idea about the 
patients’ long-term response. However, three sessions of 
pacing self-management are not intended for long-term 
improvements. Rather, they serve as the first stage (stabi-
lization phase) of a rehabilitation program designed specifi-
cally for those with CFS [14]. This study focused on the 
initial response of people with CFS to the stabilization 
phase of pacing self-management. Additional treatment 
sessions would be required to provide a comprehensive 
rehabilitation program and, hence, generate effect sizes 
similar to the ones reported in response to cognitive 
behavioral therapy [39]. On the other hand, not all 
patients with CFS can be motivated for the subsequent 
grading phase and thus will remain in a long-term stabili-
zation phase. For those patients, it would have been of 
interest to monitor the long-term responses.
As explained in detail elsewhere [14], a comprehen-
sive rehabilitation program for people with CFS com-
prises the initial stabilization phase studied here followed 
by a grading phase. During the second phase, the same 
pacing techniques are applied to grade both daily activi-
ties as well as exercise levels. When an appropriate exer-
cise level is being determined, a formal, regulated 
exercise regime that is gentle, graded, flexible, and man-
ageable according to each individual’s capabilities is 
required. Support for this type of grading for people with 
CFS comes from an observational study [40] and a well-
designed randomized controlled clinical trial, which 
reported that paced and individually tailored graded exer-
cise was superior to relaxation and flexibility training in 
patients with CFS [41]. Our view of the initial stabiliza-
tion and subsequent grading phase seems to contradict 
the adaptive pacing therapy as advocated in the ongoing 
PACE trial, in which graded exercise therapy is com-
pared with rather than preceded by the initial stabilization 
phase of our pacing program.
CONCLUSIONS 
In conclusion, the outcome of the present single
case study design suggests that 3 weeks of pacing self-
management improves symptom severity and performance
of daily activities, but a large randomized controlled evalu-
ation is required to confirm these preliminary observations.
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